



2seventy bio to Participate in Upcoming Investor Conferences

August 3, 2022 11:30 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 3, 2022-- [2seventy bio, Inc.](https://ir.2seventybio.com/) (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences:

- 2022 Wedbush PacGrow Healthcare Conference, “A View to a Kill(er Cell) – Part 1” panel on Wednesday, August 10, 2022 at 1:10 pm ET
- 42nd Annual Canaccord Genuity Growth Conference, fireside chat on Thursday, August 11, 2022 at 2:30 pm ET, the InterContinental Boston, Boston, MA

A live webcast will be available via the Investors and Media section of 2seventy bio's website at <https://ir.2seventybio.com/>. A replay will be archived on 2seventy bio's site for 30 days following the event.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. With a deep understanding of the human body's immune response to tumor cells and how to translate cell therapies into practice, we're applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: [Twitter](#) and [LinkedIn](#).

2seventy bio is a trademark of 2seventy bio, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220803005570/en/): <https://www.businesswire.com/news/home/20220803005570/en/>

Investors:

Jenn Snyder, 617-448-0281
Jenn.snyder@2seventybio.com

Media:

Morgan Adams, 774-313-9852
morgan.adams@2seventybio.com

Source: 2seventy bio, Inc.